Bryostatin 1, a natural macrolide isolated from Bugula neritina, is a potent modulator of protein kinase C (PKC) isoforms with promising anticancer properties. In numerous in vitro studies, bryostatin 1 has been shown to inhibit tumor cell proliferation and induce differentiation and apoptotic cell death in a wide range of cell lines, including leukemia, lymphoma, glioma, and solid tumors such as ovarian and breast cancer. Its antitumor activity, both as monotherapy and in combination with conventional chemotherapy, has been confirmed in in vivo models, where synergistic effects have been observed, including sensitization of tumor cells to cytostatic agents. Despite promising preclinical findings, phase I and II clinical trials have not yielded the expected results, suggesting limited efficacy of the macrolide as a single agent with a relatively favorable safety profile. Current research directions focus on optimizing dosing regimens, combining bryostatin 1 with other anticancer drugs and identifying predictive biomarkers of response. This article reviews the current state of knowledge on the anticancer effects of bryostatin 1, analyzing available data from in vitro, in vivo, and clinical trials and discussing potential directions for further translational research.

Cyclodextrins are cyclic carbohydrates capable of forming inclusion complexes with a wide range of molecules, thereby improving their solubility, stability, and bioavailability. Traditionally, cyclodextrins have been extensively applied in the food industry owing to their functionality and safety profile. However, their use in cosmeceuticals, a rapidly growing area that lies between cosmetics and pharmaceuticals, remains relatively underexplored. Given the increasing demand for scientifically validated, high-performance skincare formulations, cyclodextrins are emerging as promising compounds that can address several formulation challenges. The principal question is whether cyclodextrins represent a worthwhile investment for the future of cosmeceutical innovation. This article aims to provide a comprehensive, evidence-based overview of the current and potential roles of cyclodextrins as safe, effective, and multifunctional carriers in advanced skincare science. The current state of research on the application of cyclodextrins in cosmeceutical formulations is evaluated, with particular focus on active ingredients commonly used in dermatological care, such as vitamins A and C, coenzyme Q10, kojic acid, arbutin, and UV filters. For each of these compounds, relevant in vitro, in vivo, and clinical studies are reviewed in order to assess how cyclodextrin complexation influences key parameters, including solubility, stability, controlled release, skin penetration, and the reduction in adverse reactions. In addition, the use of cyclodextrins in the treatment of dermatological conditions such as acne, psoriasis, and rosacea is examined, highlighting their potential value, particularly in combination with azelaic acid and salicylic acid, well-known agents used to manage these conditions. Beyond their advantages, the limitations and challenges that currently restrict broader implementation of cyclodextrins in cosmeceuticals are also discussed, including cost variability, solubility constraints with certain substances, formulation incompatibilities, and regulatory considerations. Future perspectives are explored, particularly the development of novel modified and amphiphilic cyclodextrins, as well as their integration into nanotechnology-based systems and into intelligent, personalized skincare.